Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

National Cancer Institute

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

- PMLiVE

AZ boosts cardiovascular pipeline with US biotech acquisition

Its MedImmune biologics arm buys AlphaCore Pharma

- PMLiVE

Roche launches test for thyroid cancer

Elecsys Calcitonin to support diagnosis of relapse following surgery

- PMLiVE

Charity says patients worried about Cancer Drugs Fund’s future

Beating Bowel Cancer demands clarity from DH about future for access to cancer medicines in England

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links